Personalized medicine – p53 gene analysis for prediction of response to neoadjuvant therapy in esophageal cancer

摘要: The present review introduces a protocol for prospective randomized predictive marker clinical trial. study evaluates the interaction between proposed p53 and response to neoadjuvant chemotherapy in patients with potentially resectable oesophageal cancer. This trial is designed provide "level of evidence I" data, which are prerequisite implementation marker. Despite curative resection, 5-years survival rates cancer do not exceed 20%. Several phase II III studies have shown that who responded preoperative had significantly better than treated surgery alone. Up till now, it possible identify responders before commencing treatment. Eighty-four measurable disease will be enrolled pANCHO After testing genotype (p53 normal versus mutant), randomly assigned receive two different chemotherapies −5FU/Cispaltin or Docetaxel. All rendered subsequent as primary endpoint treatment evaluated. nationwide academic initiative. 13 affiliated investigational centres recruited 70% estimated within one year. Patients benefit from standardized diagnostic therapeutic procedures. supposed need new guidelines assessment patients. Marker specific results awaiting autumn 2009 could relevant choice therapy